I-Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 Purity ≥99.0% Factory
I-Linagliptin Yomkhiqizi kanye Nezixhumanisi Ezihlobene:
I-Linagliptin CAS 668270-12-0
I-Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4
I-2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0
Igama Lekhemikhali | 8-Bromo-7-kodwa-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione |
Omqondofana | I-Linagliptin Nucleus yomzali;I-Linagliptin Intermediate F |
Inombolo ye-CAS | 853029-57-9 |
Inombolo yeCAT | I-RF-PI502 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C20H17BrN6O2 |
Isisindo samangqamuzana | 453.29 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | Impushana Emhlophe Kuya Kumphuzi Okhanyayo |
Ukuhlonza | I-IR/HPLC |
Ubumsulwa | ≥99.0% |
Amanzi (KF) | ≤1.0% |
Izinsalela ekushiseni | ≤0.50% |
Ukungcola Okuphelele | ≤1.0% |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | Okumaphakathi kwe-Linagliptin (CAS: 668270-12-0) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.
I-8-Bromo-7-kodwa-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CAS: 853029-57- 9) iyi-nucleus yomzali ye-Linagliptin (CAS: 668270-12-0).I-Linagliptin (amagama ohwebo i-Tradjenta ne-Trajetna) iyisivimbeli se-dipeptidyl peptidase-4 (DPP-4) esagunyazwa yi-US FDA ngoMeyi 2011 ukuze kwelashwe isifo sikashukela soHlobo 2 kanye nokudla nokuzivocavoca.I-Linagliptin (BI-1356) ichazwe njengezinga elinamandla lokukhetha, elihamba kancane kanye ne-inhibitor esebenza isikhathi eside ye-DPP-4.I-Linagliptin iqhamuke emizamweni yokuthuthukisa ye-xanthine-based DPP-4 inhibitors ngomthofu wokuqala okhonjwe kumkhankaso we-HTS.